Medicinal Use of garlic is established since ages in different forms against various disorders. However, its efficacy against a marketed, well-known allopathy therapy is hardly been dealt with. The aim of this study was to use a standardized market preparation of Garlic, Himalaya’s herbal preparation, Lasuna capsules available in the market as Over the counter product, for comparison with the standard groups of Atorvastatin (10 mg) as well as a third combined group (comprising of both formulations) in Hyperlipidemic and/or Obese patients. A 12 weeks nonrandomized, open, parallel group clinical study was carried out to confirm these findings in patients having Hyperlipidemia and/or Obesity. Recently, hydrogen sulfide has emerged as a potential novel gaseous molecule with a promising role in protective mechanism against damage to the heart. The consumption of garlic is inversely correlated with the progression of cardiovascular disease, although the responsible mechanisms remain unclear. A study showed that human RBCs convert garlic-derived organic polysulfides into hydrogen sulfide (H2S), an endogenous cardioprotective vascular cell signaling molecule [1]. One of the study objectives was to study the release of hydrogen sulfide, the novel gastro-transmitter from this standardized, marketed formulation. The study also aimed to establish safety of the garlic formulation versus the statin therapy alone and in combination and whether the side-effects observed are tolerable. The statistical evaluation of data showed that lasuna was unable to deliver statistically significant results in a span of treatment for three months. However, it can be prescribed as a supporting regimen with Atorvastatin therapy which may be helpful in preventing an increase in dose of allopathy drug. Also, Lasuna capsules showed a marked increase in the levels of hydrogen sulfide from baseline to three months treatment, thus confirming release of H2S inside the body probably after metabolism of its active constituents.
